Ibalizumab (Trogarzo) — Prior Authorization and Coverage Criteria
Customize your policy alerts
Sign up for all careoregon policy alerts
Know when careoregon releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs prior authorization and medical necessity criteria for use of ibalizumab (Trogarzo) in adults with HIV, including initial and renewal criteria, and applies to CareOregon members and their providers.
No material clinical or coverage changes in this revision.
Coverage Criteria for Ibalizumab (Trogarzo)
Initial Therapy
Covered when ALL of the following are met:
Follow-up adherence plan required if recent non-adherence
Renewal Therapy
Covered when ALL of the following are met:
Requests for a second induction dose within 6 months of the last induction dose are not approved. This policy does not authorize repeat induction dosing during the six-month interval following a prior induction dose.
Renewal requests must include documentation of viral suppression, defined as a documented viral load of < 200 copies/mL. Renewal requests that do not demonstrate viral suppression (viral load < 200 copies/mL) are considered not medically necessary and will not be approved.
Clinical Thresholds and Coding
Provider Requirements and Authorization Details
Prior authorization required — 6 month initial approvals
Prior authorization is required for ibalizumab (Trogarzo). If initial criteria are met, approvals are for 6 months per label dosing.
Concurrent antiretroviral therapy required (no monotherapy)
Ibalizumab must be prescribed and administered in combination with other antiretroviral agents and not as monotherapy.
Required clinical documentation and lab evidence
Clinical documentation must demonstrate the indication and specialist involvement, resistance and viral load data, and adherence plans when applicable.
- Indication: treatment of HIV in an adult.
- Requestor: evidence the prescriber is an HIV or Infectious Disease specialist.
- Resistance: documentation of resistance to at least one drug in each of three classes (NRTI, NNRTI, PI).
- Failing therapy: documentation that existing therapy has failed or is failing with viral load > 1,000 copies/mL.
- Concurrent therapy: plan to use ibalizumab with additional antiretrovirals.
- Adherence: if <90% adherence to oral HIV meds in last 6 months, provide a treatment plan addressing adherence to be reviewed with plan medical staff.
- Renewal: documentation of viral suppression with viral load < 200 copies/mL.
Denial conditions — criteria not met leads to denial
Requests will be denied when the required clinical criteria or specialist documentation are not met, when the indication is not treatment of HIV in an adult, or when concurrent antiretroviral use or viral load thresholds are not satisfied.
- Do not approve if the request is not for treatment of HIV in an adult.
- Do not approve if the requestor is not an HIV or Infectious Disease specialist.
- Do not approve if there is not demonstrated resistance to at least one drug in each of three classes (NRTI, NNRTI, PI).
- Do not approve if existing therapy has not failed or is not failing with viral load > 1,000 copies/mL.
- Do not approve if ibalizumab will not be used concurrently with additional antiretrovirals.
- For renewals, do not approve if viral suppression (viral load < 200 copies/mL) is not demonstrated.
- Do not approve a second induction dose within 6 months of the last induction dose.
Background
Ibalizumab (Trogarzo) is an antiretroviral indicated for the treatment of adults with multi-drug resistant HIV-1. It is intended to be used in combination with other antiretroviral agents for patients with limited treatment options due to resistance, and specialist involvement is required for authorization decisions.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.